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accurately estimated by 2-dimensional (2D) echocardiography
using biplane methods (area–length or method of discs) (3); this
approach is recommended by the American Society of Echocar-
diography for use in clinical trials (4). Left atrial dimension
consistently underestimates left atrial volume and is therefore a
specific but insensitive test for left atrial enlargement (5). As such,
a significant proportion of patients with true left atrial enlargement
were likely categorized as normal. The authors’ qualification that
“unidimensional measurement is still the most common method
worldwide to quantify LA size,” although true, is not adequate
justification for the investigative use of an inferior measurement. A
suitable analogy would be the use of urinary dipstick testing rather
than serum glucose measurement to determine the prevalence of
diabetes in a study population.
Second, the resting ejection fraction used in the study analysis
was based on visual estimation or “eyeballing.” This technique is
not only inaccurate in determining ejection fraction compared with
2D measurement techniques, but also suffers from wide interob-
server variability and poor reproducibility (6). Moreover, the mean
ejection fraction in the patients with dilated left atria was 48%,
suggesting established systolic dysfunction at baseline rather than
“relatively preserved [left ventricular] ejection fraction,” as the
authors contend.
Third, the authors did not report or correct for Doppler indices
of diastolic dysfunction in the multivariate analysis. If, as they
suggest, left atrial size is a marker of the severity and duration of
diastolic function, then the independent prognostic value of left
atrial enlargement cannot be established without taking diastolic
dysfunction into account.
Given these methodologic concerns, the authors’ conclusion
that left atrial size should be routinely incorporated in the
prognostic interpretation of stress testing is not justified and
furthermore would be unlikely to impact clinical decision making.
For example, in the presence of a positive stress echocardiogram it
is doubtful that coronary angiography would be averted because of
the single measurement of a small left atrial dimension. Conversely
an enlarged left atrial dimension in the setting of a normal stress
echocardiogram is of unclear significance and would not, on its
own, merit further invasive workup.
Ramin Farzaneh-Far, MD
*Nelson B. Schiller, MD, FACC
*Box 0214, Department of Medicine
University of California
San Francisco, California 94143-0214
E-mail: schiller@medicine.ucsf.edu
doi:10.1016/j.jacc.2007.09.047
REFERENCES
1. Bangalore S, Yao S, Chaudhry F. Role of left atrial size in risk
stratification and prognosis of patients undergoing stress echocardiog-
raphy. J Am Coll Cardiol 2007;50:1254–62.
2. Abhayaratna WP, Seward JB, Appleton CP, et al. Left atrial size:
physiologic determinant and clinical applications. J Am Coll Cardiol
2006;47:2357–63.
3. Lester SJ, Ryan EW, Schiller NB, Foster E. Best method in clinical
practice and in research studies to determine left atrial size. Am J
Cardiol 1999;84:829–32.
4. Gottdiener JS, Bednarz J, Devereux R, et al. American Society of
Echocardiography recommendations for use of echocardiography in
clinical trials. J Am Soc Echo 2004;17:1086–119.
5. Tsang TSM, Abhayaratna WP, Barnes ME, et al. Prediction of
cardiovascular outcomes with left atrial size: is volume superior to area
or diameter? J Am Coll Cardiol 2006;47:1018–23.
6. Sievers B, Kirchberg S, Franken U, et al. Visual estimation versus
quantitative assessment of left ventricular ejection fraction: a compari-
son by cardiovascular magnetic resonance imaging. Am Heart J
2005;150:737–42.
Reply
Although we agree in principle with the views of Dr. Farzaneh-Far
and colleagues on the relative value of left atrial (LA) dimension
versus volume measurements (as we have acknowledge in the study
limitations), there is paucity of data of using any kind of LA size
measurement during stress echocardiography. The authors claim
that “left atrial volume is most accurately estimated by 2D
echocardiography using biplane methods (area-length or method
of discs)”. Studies have shown that true 3-dimensional (3D)
echocardiographic methods or simplified 3D reconstruction
method correlate better with magnetic resonance imaging-derived
LA volumes (1,2) at the expense of increased complexity of
measurement and time. Although the limitations of a LA dimen-
sion measurement are well known, given its simplicity, speed, and
reproducibility, this measure might be better applicable to patients
undergoing stress echocardiography.
Although American Society of Echocardiography recommends
using LA volume for use in clinical trials, LA dimension is still the
most commonly used measure in large multicenter clinical trials.
In the Cardiovascular Health Study of 5,888 men and women,
LA dimension was a significant predictor of future heart failure
after controlling for baseline risk factors (3). Similarly, in the
Framingham Heart Study (4) and the SPAF (Stroke Prevention in
Atrial Fibrillation) trial (5), LA dimension was related to strokes
and death in the former and to thromboembolic events (e.g.,
strokes and transient ischemic attacks) in the latter. Even in the
more recent trials like the LIFE (Losartan Intervention for
Endpoint reduction in hypertension) trial, LA diameter/height
predicted risk of cardiovascular events independent of other clinical
risk factors in hypertensive patients with left ventricular hypertro-
phy (6). In our study we have shown that there was strong
interobserver (interclass correlation [ICC]  0.977) and intraob-
server (ICC  0.980) correlations for the measurement of LA
dimension (7).
We have discussed the relative value of using LA size as a
marker of diastolic function on the basis of prior studies—it
reflects the chronicity and magnitude of the increased left ventric-
ular filling pressure (8) and is thus a marker of the severity and
duration of diastolic dysfunction (9). It has been suggested (10)
that Doppler indexes of diastolic function reflect filling pressures at
1 point in time and hence LA size might be a better marker,
because it represents the chronicity of diastolic function. Given this
data from previous studies, we did not correct for Doppler indexes
of diastolic dysfunction in the multivariate analysis.
With regard to the accuracy of visually estimated left ventricular
ejection fraction, prior studies have shown strong correlation of
visually estimated left ventricular ejection fraction with radionu-
clide angiography (11).
Finally, although we do agree that “enlarged left atrial dimen-
sion in the setting of a normal stress echocardiogram is of unclear
significance, and would not, on its own, merit further invasive
workup,” it should be emphasized that, in the setting of a normal
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stress echocardiography study, patients with enlarged left atrium
have 3.4 times the event rate of a normal LA size (0.5%/year vs.
1.7%/year). This might not merit further invasive workup. How-
ever, it does merit aggressive medical management of risk factors,
because an event rate of 1.7%/year cannot be considered as benign
as the same event rate in a mildly abnormal stress echocardiogra-
phy study (wall motion score index 1.1 to 1.7) (12). Thus, we
disagree with Dr. Farzaneh-Far and colleagues that LA size should
not be incorporated into risk stratification. In echocardiography as
in other imaging techniques, evaluating multiple parameters de-
fines diagnostic and prognostic data more accurately. As stated in
our article, “further studies using LA volumes are needed to
elucidate the role of diastolic dysfunction in patients undergoing
stress echocardiography and to further evolve the concept of
diastolic stress echocardiography.”
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Beta-Blocker
Therapy in Hypertension:
A Need to Pause and Reflect
The recent State-of-the-Art Paper by Bangalore et al. (1) ques-
tioned the utility of betablockers as first-line treatment for “un-
complicated” hypertension. Although the authors indicate that
they “do not want to throw the baby out with the bathwater,” we
are concerned that the overall tone of the article is so negative that
this indeed might happen. Thus, we believe that the following
comments might be helpful when clinicians are deciding whether
or not to use beta-blockers in a particular patient.
Bangalore et al. (1) cited a lack of benefit with beta-blockers in
reducing all-cause or cardiovascular mortality and myocardial
infarction from a meta-analysis by Lindholm et al. (2); in fact, no
difference was observed for these end points versus other anti-
hypertensives. Some of the early assessments of beta-blockers,
including the STOP-1 and -2 (Swedish Trial in Old Patients with
Hypertension-1 and -2), showed that beta-blockers reduced total
and cardiovascular morbidity compared with placebo and that the
results were similar to angiotensin-converting enzyme (ACE)
inhibitors and calcium channel blockers (3,4).
Most of the evidence summarized by Bangalore et al. (1)
concern studies of atenolol. However, the authors neglected to
point out that the less favorable clinical outcomes seen with
atenolol versus other therapies might be due to an absence of 24-h
efficacy when it is used once daily at a dose of 50 mg. In fact, the
INVEST (International Verapamil-Trandolapril Study) demon-
strated no difference in outcomes between a beta-blocker– and
calcium-antagonist–based regimen (5). Notably, in this trial
atenolol was dosed twice daily. Similarly, data from the UKPDS
(United Kingdom Prospective Diabetes Study) also showed ateno-
lol to have efficacy similar to an ACE inhibitor regimen in
preventing macrovascular complications in hypertensive diabetic
patients (6).
We also believe that the term, “pseudo antihypertensive” effi-
cacy, is misleading, because the authors probably refer to relative
blood pressure reductions as distinct from the efficacy of treating
the disease, hypertension. As the authors point out, beta-blockers
are important for treating a wide range of high-risk cardiovascular
conditions.
We agree with the authors that, historically, use of traditional
beta-blockers has been constrained by associated side effects, in
particular, fatigue and sexual dysfunction. However, there is
mounting evidence showing that the side effect profile of vasodi-
latory beta-blockers is markedly different and comparable to
placebo (7,8). Vasodilating beta-blockers also demonstrate neutral
or beneficial metabolic profiles. As cited by the authors, the
GEMINI (Glycemic Effects in Diabetes Mellitus: Carvedilol-
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